Effect of Psychological and Medication Therapies for Insomnia on Daytime Functions

唑吡坦 失眠症 心情 医学 失眠的认知行为疗法 随机对照试验 物理疗法 认知行为疗法 精神科 曲唑酮 内科学 焦虑 抗抑郁药
作者
Charles M. Morin,Sijing Chen,Hans Ivers,Simon Beaulieu‐Bonneau,Andrew D. Krystal,Bernard Guay,Lynda Bélanger,Ann Cartwright,Bryan Simmons,Manon Lamy,Mindy Busby,Jack D. Edinger
出处
期刊:JAMA network open [American Medical Association]
卷期号:6 (12): e2349638-e2349638 被引量:20
标识
DOI:10.1001/jamanetworkopen.2023.49638
摘要

Importance: Daytime functional impairments are the primary reasons for patients with insomnia to seek treatment, yet little is known about what the optimal treatment is for improving daytime functions and how best to proceed with treatment for patients whose insomnia has not remitted. Objectives: To compare the efficacy of behavioral therapy (BT) and zolpidem as initial therapies for improving daytime functions among patients with insomnia and evaluate the added value of a second treatment for patients whose insomnia has not remitted. Design, Setting, and Participants: In this sequential multiple-assignment randomized clinical trial conducted at institutions in Canada and the US, 211 adults with chronic insomnia disorder were enrolled between May 1, 2012, and December 31, 2015, and followed up for 12 months. Statistical analyses were performed on an intention-to-treat basis in April and October 2023. Interventions: Participants were randomly assigned to either BT or zolpidem as first-stage therapy, and those whose insomnia had not remitted received a second-stage psychological therapy (BT or cognitive therapy) or medication therapy (zolpidem or trazodone). Main Outcomes and Measures: Study outcomes were daytime symptoms of insomnia, including mood disturbances, fatigue, functional impairments of insomnia, and scores on the 36-item Short-Form Health Survey (SF-36) physical and mental health components. Results: Among 211 adults with insomnia (132 women [63%]; mean [SD] age, 45.6 [14.9] years), 104 were allocated to BT and 107 to zolpidem at the first stage. First-stage treatment with BT or zolpidem yielded significant and equivalent benefits for most of the daytime outcomes, including depressive symptoms (Beck Depression Inventory-II mean score change, -3.5 [95% CI, -4.7 to -2.3] vs -4.3 [95% CI, -5.7 to -2.9]), fatigue (Multidimensional Fatigue Inventory mean score change, -4.7 [95% CI, -7.3 to -2.2] vs -5.2 [95% CI, -7.9 to -2.5]), functional impairments (Work and Social Adjustment Scale mean score change, -5.0 [95% CI, -6.7 to -3.3] vs -5.1 [95% CI, -7.2 to -2.9]), and mental health (SF-36 mental health subscale mean score change, 3.5 [95% CI, 1.9-5.1] vs 2.5 [95% CI, 0.4-4.5]), while BT produced larger improvements for anxiety symptoms relative to zolpidem (State-Trait Anxiety Inventory mean score change, -4.1 [95% CI, -5.8 to -2.4] vs -1.2 [95% CI, -3.0 to 0.5]; P = .02; Cohen d = 0.55). Second-stage therapy produced additional improvements for the 2 conditions starting with zolpidem at posttreatment in fatigue (Multidimensional Fatigue Inventory mean score change: zolpidem plus BT, -3.8 [95% CI, -7.1 to -0.4]; zolpidem plus trazodone, -3.7 [95% CI, -6.3 to -1.1]), functional impairments (Work and Social Adjustment Scale mean score change: zolpidem plus BT, -3.7 [95% CI, -6.4 to -1.0]; zolpidem plus trazodone, -3.3 [95% CI, -5.9 to -0.7]) and mental health (SF-36 mental health subscale mean score change: zolpidem plus BT, 5.3 [95% CI, 2.7-7.9]; zolpidem plus trazodone, 2.0 [95% CI, 0.1-4.0]). Treatment benefits achieved at posttreatment were well maintained throughout the 12-month follow-up, and additional improvements were noted for patients receiving the BT treatment sequences. Conclusions and Relevance: In this randomized clinical trial of adults with insomnia disorder, BT and zolpidem produced improvements for various daytime symptoms of insomnia that were no different between treatments. Adding a second treatment offered an added value with further improvements of daytime functions. Trial Registration: ClinicalTrials.gov Identifier: NCT01651442.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
可爱忆安完成签到,获得积分10
刚刚
小雨完成签到,获得积分10
1秒前
1234567发布了新的文献求助10
1秒前
1秒前
Elsevier大王的应助被谷长云采纳,获得30
3秒前
3秒前
3秒前
华仔的应助被Connie采纳,获得10
4秒前
4秒前
亢kxh完成签到,获得积分10
5秒前
海晏完成签到 ,获得积分10
6秒前
7秒前
7秒前
淡定的豌豆完成签到 ,获得积分10
7秒前
8秒前
丁丁当当发布了新的文献求助10
8秒前
搜集达人的应助被山风采纳,获得10
8秒前
高兴发布了新的文献求助10
9秒前
小羊发布了新的文献求助10
9秒前
11秒前
ehsl完成签到,获得积分10
11秒前
荼蘼发布了新的文献求助30
13秒前
CodeCraft的应助被科研通管家采纳,获得10
14秒前
14秒前
xucc发布了新的文献求助10
14秒前
14秒前
上官若男的应助被科研通管家采纳,获得10
14秒前
汉堡包的应助被科研通管家采纳,获得10
15秒前
酷波er的应助被科研通管家采纳,获得10
15秒前
Lucas的应助被王佳佳采纳,获得10
15秒前
研友_VZG7GZ的应助被科研通管家采纳,获得30
15秒前
顺利的盼曼关注了科研通微信公众号
15秒前
完美世界的应助被科研通管家采纳,获得10
15秒前
15秒前
李爱国的应助被科研通管家采纳,获得10
15秒前
15秒前
xinyuanjia的应助被科研通管家采纳,获得30
16秒前
人间一两风完成签到 ,获得积分10
16秒前
CCC发布了新的文献求助10
16秒前
丘比特的应助被科研通管家采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175142
求助须知:如何正确求助?哪些是违规求助? 9566928
关于积分的说明 21789123
捐赠科研通 7769522
什么是DOI,文献DOI怎么找? 3431822
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477222